GoKawiilEli Lilly to acquire AtaiBeckley for up to $3.8bn in psychedelic drug push
Eli Lilly announced in July plans to acquire psychedelic-medicine developer AtaiBeckley for up to $3.8 billion, targeting its lead drug BPL-003 for treatment-resistant depression. The deal follows AbbVie's $1.2 billion acquisition earlier in 2025 of Gilgamesh Pharmaceutical's short-acting psychedelic bretisilocin, signaling renewed big-pharma interest despite the FDA's 2023 rejection of an MDMA-based PTSD treatment.